Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab alone versus ranibizumab plus macular laser for macular edema secondary to branch retinal vein occlusion
ChiCTR1800014289Phase 4Recruiting
- Sponsor
- Beijing Hospital
- Start
- Sep 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ranibizumab in branch retinal vein occlusion (BRVO) and macular edema (2 arms), sponsored by Beijing Hospital. Primary endpoint: Edema height. Started Sep 2016; status: recruiting.
02
Drugs
ranibizumab
03
Conditions
branch retinal vein occlusion (BRVO)macular edema
Beyond the preview
Go deeper on ChiCTR1800014289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014289.